May 2018 in “International Journal of Advances in Medicine” A young woman recovered well from rare simultaneous Hepatitis B and autoimmune hepatitis after treatment.
1 citations
,
September 2013 in “The Journal of Dermatology” An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
1 citations
,
July 2025 in “Frontiers in Endocrinology” ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.
January 2014 in “Journal of Jilin University” Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.
April 2023 in “Journal of Investigative Dermatology” CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.
1 citations
,
February 2023 in “Pharmaceutics” Cell proteomic footprinting enhances cancer vaccine quality by ensuring correct antigen composition.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
18 citations
,
December 1992 in “Journal of Cutaneous Pathology” Skin tumors and normal skin structures have different lectin-binding patterns.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
February 2009 in “Journal of The American Academy of Dermatology” Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.
June 2021 in “Working paper of public health” Six months after COVID-19, most patients still had autoantibodies.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
13 citations
,
June 2024 in “Asian Pacific Journal of Cancer Prevention” The (+) enantiomer of YH239-EE effectively kills breast cancer cells.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
November 2025 in “Indian Journal of Nephrology” Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
20 citations
,
March 1985 in “Journal of The American Academy of Dermatology” Genetic factors alone might not cause pemphigus vulgaris; other factors like birth complications and puberty may trigger it.
November 2025 in “Journal of Investigative Dermatology” PCFCL may have unrecognized subtypes and needs more research.
13 citations
,
June 2012 in “European journal of medical genetics” Identical twins had different symptoms because one had more cells with an extra chromosome fragment in different tissues.
105 citations
,
September 1995 in “Journal of The American Academy of Dermatology” Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.
3 citations
,
September 2025 in “ChemMedChem” Multitarget drugs are needed to better treat complex diseases.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.